Product Overview

»	Benefits and Features
»	Feline UltraNasal^® Vaccines — A Progressive Alternative
»	Safe and Effective
»	Easy to Administer

Benefits and Features

Benefits

Provide rapid protection against the most prevalent causes of feline upper respiratory disease (rhinotracheitis virus and calicivirus), plus excellent protection from feline panleukopenia.
Safe, effective alternatives to injectable vaccines.
Intranasally administered.
No needles required to use the vaccines.
Eliminate the risk of injection-site sarcomas and reactions.

Features

Convenient, easily administered 0.2 mL dose.
Rapid local immunity for upper respiratory viruses in 2 – 4 days.
Protection with a single mucosal dose.
Can be used in kittens 4 weeks of age and older.
Intranasal modified-live virus FVRCP vaccine is a type of vaccine recommended by AAFP (American Association of Feline Practitioners) Vaccination Guidelines.

Feline UltraNasal^® Vaccines — A Progressive Alternative

At Heska, we're working hard to provide you meaningful solutions in your practice. Introducing NEW Feline UltraNasal^® Vaccines — providing safe, needle-free protection against the most prevalent causes of feline upper respiratory disease and panleukopenia.

These vaccines provide rapid immunity in both cats and kittens with a single 0.2 mL dose — without the risk of injection site sarcoma.

Feline UltraNasal^® FVRCP (rhinotracheitis virus, calicivirus and panleukopenia virus) Vaccine and Feline UltraNasal^® FVRC (rhinotracheitis virus and calicivirus) Vaccine are progressive alternatives that can really make a difference for your patients and in your practice.

Safe and Effective

Laboratory studies were conducted to prove the Feline UltraNasal^® Vaccines provide rapid and effective immunity against feline rhinotracheitis virus, feline calicivirus and panleukopenia virus.
To immunize cats against upper respiratory disease, a 0.2 mL dose of Heska’s FVRC vaccine may be administered to kittens as young as 4 weeks of age to provide protective immunity against feline rhinotracheitis and feline calicivirus.
For protection against upper respiratory disease and panleukopenia virus, a 0.2 mL dose of Heska’s FVRCP vaccine may be administered to cats 4 weeks of age or older.
When compared to unvaccinated control cats, vaccinated cats had evidence suggesting early protection against virulent herpesvirus 1 challenge as early as two days post-vaccination with significant protection being detected by four days post-vaccination.^1,5 Data generated in another study suggested vaccination of previously uninfected cats via the intranasal route may prevent the subsequent development of a rhinotracheitis virus carrier state following challenge with virulent field virus, at least in the short term.²
The safety of the vaccines also was tested.³ The most common clinical sign observed was transient sneezing. Vaccinated cats recovered without incident.
FVRCP vaccines administered subcutaneously induce a statistically significant antibody response against kidney cells. The intranasally administered Feline UltraNasal^® Vaccines do not.⁴ Currently, the relationship between these antibodies and feline kidney disease is not known and is the subject for ongoing research.

Cocker, F.M., et al., (1986) Interaction of an intranasal combined feline viral rhinotracheitis, feline calicivirus vaccine and the FVR carrier state Research in Veterinary Science 41, 323-330.
Orr, C.M., et al., (1980) Responses of cats to nasal vaccination with a live, modified feline herpesvirus type 1. The Veterinary Record 106, 164-166.
Field Trial Study on file at USDA.
Lappin, M., et al., (2004) ACVIM Abstract #198, Magnitude of Crandell Reese Feline Kidney Cell Line Antibody Responses of Cats Administered FVRCP Vaccines.
Lappin MR, Sebring RW, Porter M, et al. Effects of a single dose of an intranasal feline herpesvirus 1, calicivirus, and panleukopenia vaccine on clinical signs and virus shedding after challenge with virulent herpesvirus 1. J Fel Med Surg In review, 2004.

Easy to Administer

Administering this intranasal vaccine is easy. Just transfer the 0.2 mL of the liquid vaccine into the lyophilized vaccine, mix and apply equal amounts into each nostril.

» See how easy administration can be.